Recombinant allergens for immunotherapy

Allergy and Asthma Proceedings

Volumn 23, Issue 1, 2002, Pages 5-8

  Chapman, Martin D ^a,b   Smith, Alisa M ^a   Vailes, Lisa D ^a   Pomés, Anna ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b INDOOR Biotechnologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN;

DESENSITIZATION; GENETIC RECOMBINATION; GENETICS; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; REVIEW;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; RECOMBINATION, GENETIC;

EID: 0036359175     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Noon L. Prophylactic immunization against hayfever. Lancet i: 1572, 1911.
2. Bousquet J, Lockey RF, and Malling HJ. WHO Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 53:1-42. 1998
3. Adkinson NF Jr, Rggleston PA, Eney D, et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 336: 324-331, 1997.
4. Durham SR, Walker SM, Varga BM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 341:468-475, 1999.
5. Chapman MD, Smith AM, V ailes LD, et al. Recombinant allergens for diagnosis and therapy of allergic disease. J Allergy Clin Immunol 106-409-418, 2000.
6. Valenta R, Lidholm J, Niederberger V, et al. The recombinant allergen-based concept of component resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy 29:896-904, 1999.
7. Shakib F, and Gough L. The proteolytic activity of Der p 1 selectively enhances IgE synthesis: a link between allergenicity and cysteine protease activity. Clin Exp Allergy 30:751-752, 2000.
8. Akdis, CA, Akdis M, Blesken T, et al. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by 1L-2 and IL-15 in vitro. J Clin Invest 98:1676-1683, 1996.
9. Hoyne GF, Tan K, Corsin-Jimenez M, et al. Immunological tolerance to inhaled antigen. Am J Respir Crit Care Med 162:5169-8174, 2000.
10. Haselden BM, Kay AB, and Larche M. Peptide-mediated immune responses in specific immunotherapy. Int Arch Allergy Immunol 122:229-237, 2000.
11. Secrist H, Chelen CJ, Wen Y, et al. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med 178:2123-2130, 1993.
12. Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest 102:98-106, 1998.
13. Platts-Mills TAE, Vaughart J, Squillace S, et al. Sensitisation, asthma, and modified Th2 r, asthma, and modified Th2 r, asthma, and modified Th2 r, asthma, and modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet 357:752-756, 2001.
14. Hoyne GF, O'Hehir RE, Wraith DC, et al. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J Exp Med 178:1783-1788, 1993.
15. Norman PS, Ohman JL, Long AA, et al. Treatment of cat allergy with T cell reactive peptides. Am J Respir Crit Care Med 164:1623-1628, 1996.
16. Maguire P, Nicodemus C, Robinson D, et al. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 93:222-231, 1999.
17. Pene J, Desroches A, Paradis L, et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 102:571-578, 1998.
18. Larche M, Haselden BM. Oldfield W, et al. Mechanisms of T cell peptide epitiope-dependent late asthmatic reactions. Int Arch Allergy Immunol 124:272-275, 2001.
19. Smith AM, and Chapman MD. Reduction in IgE binding to allergen variants generated by site-directed mutagenesis: contribution of disulfide bonds to the antigenic structure of the major house dust mite allergen, Der p 2. Mol Immunol 33:399-405, 1996.
20. Takai T, Yokota T, Yasue M, et al. Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. Nat Biotechnol 15:754-758, 1997.
21. Hakkaart GA, Aalberse RC, and van Ree R. Epitope mapping of the house-dust-mite allergen Der p 2 by means of site-directed mutagenesis. Allergy 53:165-172, 1998.
22. Olsson S, van Hage-Hamsten M, and Whitley P. Contribution of disulphide bonds to antigenicity of Lep d 2, the major allergen of the dust mite Lepidoglyphus destructor. Mol Immunol 35:1017-1023, 1998.
23. Schramm G, Kahlert H, Suck R, et al. "Allergen engineering": variants of the timothy grass pollen allergen Phl p 5b with reduced IgE-binding capacity but conserved T cell reactivity. J Immunol 162:2406-2413, 1999.
24. Ferreira F, Ebner C, Kramer B, et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J 12:231-242, 1998.
25. Pauli G, Purohit A, Oster JP, et al. Comparison of genetically engineered hypoallergenic rBet v 1 derivatives with rBet v 1 wild-type by skin prick and intradermal testing; results obtained in a French population. Clin Exp Allergy 30:1076-1084, 2000.
26. Nopp A, Hallden G, Lundahl J, et al. Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen Bet v 1 and to recombinant Bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. J Allergy Clin Immunol 106:101-109, 2000.
27. Van Hage-Hamsten M, Kronqvist M, Zetterstrom O, et al. Skin test evaluation of genetically engineered hypoallergenic derivatives of the major birch pollen allergen. Bet v 1 : results obtained with a mix of two recombinant Bet v 1 fragments and recombinant Bet v 1 trimer in a Swedish population before the birch pollen season. J Allergy Clin Immunol 104:969-977, 1999.
28. Bannon GA, Cockrell G, Connaughton C, et al. Engineering, characterization and in vitro efficacy of the major peanut allergens for use in immunotherapy. Int Arch Allergy Immunol 124:70-72, 2001.
29. Van Uden J, and Raz E. Immunostimulatory DNA and applications to allergic disease. J Allergy Clin Immunol 104:902-910, 1999
30. Hsu CH, Chua KY, Tao MH, et al. Immunoprophylaxis of allergen-induced immunoglobulin E synthesis and airway hyperresponsiveness in vivo by genetic immunization. Nat Med 2:540-544, 1996.
31. Tighe H, Takabayashi K, Schwartz D, et al. Conjungation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 106:124-134, 2000.